AstraZeneca: Phase III Truqap Trial Plus Chemotherapy Fails To Meet Primary Goals In Breast Cancer

(RTTNews) - British drug major AstraZeneca Plc. (AZN.L, AZN) announced Tuesday that the CAPItello-290 Phase III trial for Truqap (capivasertib) plus chemotherapy in patients with locally advanced (inoperable) or metastatic triple-negative breast cancer or TNBC did not meet the du https://www.nasdaq.com/articles/astrazeneca-phase-iii-truqap-trial-plus-chemotherapy-fails-meet-primary-goals-breast